Wall Street analysts expect the company to post Earnings Per Share (EPS) of $0.93 on revenue of $5.12 billion.
Wall Street analysts expect Snowflake to post Earnings Per Share (EPS) of $0.15 on revenue of $899.31 million.
The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.
Richard N. Altice, Interim CEO of Danimer, said the company is focused on preserving liquidity and looking at a “variety of transactions” to strengthen its capital structure.
Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2; Piper Sandler upgraded the company to ‘Overweight’ from ‘Neutral.’
Danon disease is a rare genetic disorder whose complications can ultimately cause heart failure, and for male patients, frequent death.
Retail sentiment on the stock dipped to ‘bearish’ (43/100) from ‘neutral’ (46/100) a day ago.
For the quarter ending September 30, Inovio reported a loss of $0.89 per share, beating analyst estimates of a $1.15 loss per share, according to Stocktwits data.
Analysts from Cantor Fitzgerald, Canaccord, Benchmark, and Roth MKM raised their price targets for Intuitive Machines, citing strong growth prospects driven by upcoming lunar missions, a robust backlog,...
Retail sentiment on the stock dipped to ‘bullish’ from ‘extremely bullish’ last week.